Development of novel endosome-targeted Ebola virus entry inhibitors as antiviral agents
开发新型内体靶向埃博拉病毒进入抑制剂作为抗病毒药物
基本信息
- 批准号:9431045
- 负责人:
- 金额:$ 61.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-03-01 至 2021-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffinityAfricaAntiviral AgentsAntiviral TherapyAntiviral resistanceBindingBiodistributionBiological AssayBiological AvailabilityBiophysicsC-PeptideCell Culture TechniquesCellsCentral AfricaChronicCouplesDemocratic Republic of the CongoDevelopmentDiseaseDisease OutbreaksDominant-Negative MutationEbola Hemorrhagic FeverEbola virusEndocytosisEndosomesEpidemicEvaluationEvolutionFamilyFiloviridae InfectionsFilovirusFrankfurt-Marburg Syndrome VirusGP2 geneGTPBP1 geneGlutamineGlycoproteinsHandHumanIn VitroIndividualInfectionIntegration Host FactorsKnowledgeLeadLeucineLipidsMediatingMembraneMembrane FusionMolecularMolecular ConformationMusMutagenesisNamesPeptidesPersonsPlasmaProcessProphylactic treatmentProtein EngineeringProteinsRouteScanningSolubilityStructureSurfaceTestingTherapeuticToxic effectVaccinesViralViral Hemorrhagic FeversVirusVirus DiseasesWorkanalogaqueousc newcytotoxicitydesignendosome membraneexperimental studyfundamental researchimmunogenicityimprovedin vivoinhibitor/antagonistintraperitoneallead candidatemortalitymouse modelnanomolarnonhuman primatenovelparenteral administrationpathogenpeptide Apeptide analogpolypeptide Cpreventprotein aminoacid sequencepublic health relevancesubcutaneousuptakeviral resistancevirus envelope
项目摘要
DESCRIPTION: Ebola viruses (EBOV) and Marburg virus (MARV) are two genera of enveloped viruses that constitute the family of Filoviridae. Outbreaks of fulminant hemorrhagic fever in human and non-human primates in Central Africa caused by EBOV have reached mortality rates of up to 90% in the past and the mortality rate in the recent West Africa outbreak is 60%. No specific antiviral treatment or vaccine is approved for these deadly pathogens. There is thus an urgent need to develop effective antiviral therapies against infection by filoviruses. Targeting
cell entry of enveloped viruses as an antiviral strategy has been proven effective against a wide range of viral diseases. However, the intracellular sequestration of filovirus fusion machinery makes it challenging to develop antivirals that block EBOV glycoprotein (GP)-mediated viral entry. We aim to overcome this challenge by adding a cell penetrating peptide sequence and conjugating a lipid moiety to fusion inhibitory peptides (C-peptides). We have shown that sustained plasma levels of our lipid-conjugated EBOV C-peptide are achieved after parenteral administration in mice. This C-peptide inhibits in vitro infection by EBOV with an IC50 of 0.2 M
and efficiently protects mice from lethal EBOV infection. We propose to leverage these preliminary results to design, synthesize and evaluate novel EBOV C-peptide analogs that can be delivered intranasally or subcutaneously, and have enhanced efficacy against a broad range of filoviruses. Analogs will be evaluated for antiviral activity in infectivity assays, for cytotoxcity on human cells, and for GP2 subdomain-binding interactions. Promising analogs will be evaluated for in vitro antiviral activity against diverse filoviruses and for toxicity in mice. We ill also identify the molecular determinants of antiviral resistance. Selected analogs will be tested in challenge experiments in a mouse model. We anticipate that the knowledge gained from our proposed studies will significantly enhance our ability to address the threat of natural and intentional epidemics by developing potent antiviral drugs with feasible delivery routes for containing acute filovirus outbreaks. We propose the following specific aims: Aim 1. To use structure-guided mutagenesis and protein engineering to optimize the antiviral potency and bioavailability of EBOV C-peptide inhibitors. a) Design and synthesis of new C-peptide analogs; b) Characterization of antiviral activity against a range of filoviruses in cell culture; c) Characterization of determinants of viral resistance by in vitro virus evolution experiments. Aim 2. To evaluate the protection afforded by novel EBOV C-peptide inhibitors delivered intranasally or parenterally against lethal EBOV infection in mice. a) Analysis of in vivo biodistribution of improved EBOV C-peptide analogs; b) Evaluation of toxicity in mice; c) Assessment of in vivo potency and breadth of activity of fusion inhibitors in the mouse model of EBOV infection.
描述:埃博拉病毒(EBOV)和马尔堡病毒(MARV)是构成丝状病毒科的两个包膜病毒属。在中非,由EBOV引起的人和非人灵长类动物暴发性出血热的死亡率在过去已达到90%,最近西非暴发的死亡率为60%。没有针对这些致命病原体的特定抗病毒治疗或疫苗被批准。因此,迫切需要开发针对丝状病毒感染的有效抗病毒疗法。靶向
作为抗病毒策略的包膜病毒的细胞进入已被证明对广泛的病毒性疾病有效。然而,丝状病毒融合机制的细胞内隔离使得开发阻断EBOV糖蛋白(GP)介导的病毒进入的抗病毒药具有挑战性。我们的目标是通过添加细胞穿透肽序列并将脂质部分与融合抑制肽(C肽)缀合来克服这一挑战。我们已经表明,在小鼠中肠胃外施用后,实现了我们的脂质缀合的EBOV C肽的持续血浆水平。该C肽抑制EBOV的体外感染,IC 50为0.2 μ M
并有效地保护小鼠免受致死性EBOV感染。我们建议利用这些初步结果来设计、合成和评估新的EBOV C肽类似物,其可以鼻内或皮下递送,并且对广泛的丝状病毒具有增强的功效。将在感染性试验中评价类似物的抗病毒活性、对人细胞的细胞毒性以及GP 2亚结构域结合相互作用。将评估有前景的类似物对不同丝状病毒的体外抗病毒活性和小鼠毒性。我们还将确定抗病毒药物耐药性的分子决定因素。将在小鼠模型中的激发实验中测试选定的类似物。我们预计,从我们拟议的研究中获得的知识将通过开发具有可行的递送途径的强效抗病毒药物来控制急性丝状病毒爆发,从而显着提高我们应对自然和故意流行病威胁的能力。我们提出以下具体目标:目标1。利用结构导向突变和蛋白质工程优化埃博拉病毒C肽抑制剂的抗病毒效力和生物利用度。a)新的C-肽类似物的设计和合成; B)在细胞培养物中对一系列丝状病毒的抗病毒活性的表征; c)通过体外病毒进化实验表征病毒抗性的决定因素。目标二。评价鼻内或胃肠外给药的新型EBOV C肽抑制剂对小鼠致死性EBOV感染的保护作用。a)分析改进的EBOV C-肽类似物的体内生物分布; B)评价小鼠中的毒性; c)评估融合抑制剂在EBOV感染的小鼠模型中的体内效力和活性宽度。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matteo Porotto其他文献
Matteo Porotto的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matteo Porotto', 18)}}的其他基金
Design of fusion inhibitors to block measles host-to-host infection
设计融合抑制剂来阻止麻疹宿主间感染
- 批准号:
10753711 - 财政年份:2023
- 资助金额:
$ 61.08万 - 项目类别:
Design of fusion inhibitors to block measles host-to-host infection
设计融合抑制剂来阻止麻疹宿主间感染
- 批准号:
10457081 - 财政年份:2021
- 资助金额:
$ 61.08万 - 项目类别:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
阻止 SARS-CoV-2 宿主间传播的融合抑制剂
- 批准号:
10457959 - 财政年份:2021
- 资助金额:
$ 61.08万 - 项目类别:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
阻止 SARS-CoV-2 宿主间传播的融合抑制剂
- 批准号:
10668973 - 财政年份:2021
- 资助金额:
$ 61.08万 - 项目类别:
Fusion inhibitors that block host-to-host transmission of SARS-CoV-2
阻止 SARS-CoV-2 宿主间传播的融合抑制剂
- 批准号:
10237600 - 财政年份:2021
- 资助金额:
$ 61.08万 - 项目类别:
Small molecules to block measles spreading in the central nervous system
小分子阻止麻疹在中枢神经系统中传播
- 批准号:
9986209 - 财政年份:2019
- 资助金额:
$ 61.08万 - 项目类别:
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
开发治疗麻疹脑炎的融合抑制肽
- 批准号:
10414909 - 财政年份:2018
- 资助金额:
$ 61.08万 - 项目类别:
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
开发治疗麻疹脑炎的融合抑制肽
- 批准号:
10178126 - 财政年份:2018
- 资助金额:
$ 61.08万 - 项目类别:
Development of therapeutic fusion inhibitor peptides for Measles encephalitis
开发治疗麻疹脑炎的融合抑制肽
- 批准号:
9973101 - 财政年份:2018
- 资助金额:
$ 61.08万 - 项目类别:
Self-assembling nanoparticles for intranasal delivery of influenza fusion inhibitors
用于鼻内递送流感融合抑制剂的自组装纳米颗粒
- 批准号:
9441694 - 财政年份:2016
- 资助金额:
$ 61.08万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 61.08万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 61.08万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 61.08万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 61.08万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 61.08万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 61.08万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 61.08万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 61.08万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 61.08万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 61.08万 - 项目类别:
Research Grant